Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO

 
• By Ian Schofield

With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.

Reducing costs
Greater use of biosimilars, particularly in cancer, can save on healthcare costs

Biosimilars in Europe have made a strong start to 2017, with three new drug approvals, backing from the European Society for Medical Oncology, and the first biosimilar anticancer awaiting imminent approval.

Meanwhile, the European Commission has published a new question and answer document explaining the ins and outs of biosimilars for patients, and the European Medicines Agency and the European Directorate for the Quality of Medicines and

More from Biosimilars

More from Biosimilars & Generics